Abstract:Tuberculosis is reported to be associated with the severity and mortality amongst patients with coronavirus disease 2019 (COVID-19).1 However, the reported prevalence of comorbid tuberculosis amongst COVID-19 patients varied greatly across the published studies. For example, the low prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Tian et al's study (0.4%)2 and Yan et al's study (0.2%)3 and the relatively high prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Hu et al's study (4.5%)4 and Zhang et al's study (9.0%).5 Therefore, it is needed to quantitatively estimate the pooled prevalence of comorbid tuberculosis amongst COVID-19 patients using a meta-analysis. A systematic literature search was conducted independently by two investigators in PubMed, Web of Science, EMBASE, Springer, Elsevier-ScienceDirect, Wiley Online Library, Scopus and Cochrane Library databases to select all eligible studies which were published from 1 January 2020 to 31 August 2021. The following keywords were used: "prevalence" or "incidence" or "rate" or "characteristics" and "tuberculosis" and "COVID-19" or "SARS-CoV-2" or "2019-nCoV" or "severe acute respiratory syndrome coronavirus 2" or "coronavirus disease 2019" or "2019 novel coronavirus". All peer-reviewed papers which were published in the English language were eligibly included if they provided the incidence rate of comorbid tuberculosis amongst COVID-19 patients. Accordingly, we excluded case reports, review articles, duplicate publications, errata, comments and preprints. Reference lists of the retrieved articles were also screened to identify additional studies. This rapid systematic review and meta-analysis was performed following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).6 The pooled prevalence of comorbid tuberculosis amongst COVID-19 patients was estimated using a random effects meta-analysis model.7, 8 The statistical heterogeneity across studies was assessed by I2 statistic and Cochrane Q test.9, 10 The risk of publication bias was evaluated by Begg's rank correlation test.11, 12 All statistical analyses were carried out using the package "meta" on R version 3.6.3 (R Foundation for Statistical Computing). A two-tailed P value <.05 was regarded statistically significant. A total of 114 eligible studies2-5, 13-122 with 405 596 COVID-19 patients were included in this meta-analysis. Amongst the included studies, 77 studies2-5, 13-85 were reported in Asia, 15 studies90-100 were conducted in Africa, nine studies101-109 were conducted in South America, five studies110-114 were performed in North America, seven studies115-121 were conducted in Europe and one study122 was from multicountries. The baseline characteristics of the included studies are summarised in Table 1. Overall, our findings demonstrated that the prevalence of comorbid tuberculosis amongst COVID-19 patients in this pooled meta-analysis was 1.6% with 95% confidence interval (CI): 1.3%–1.9% (Figure 1). The regional tuberculosis prevalence in COVID-19 patients was estimated as follows: Africa (4.1%, 95% CI: 0.0%–5.8%), Asia (1.1%, 95% CI: 0.9%–1.3%), South America (0.5%, 95% CI: 0.0%–1.0%), Europe (0.4%, 95% CI: 0.0%–0.6%) and North America (0.2%, 95% CI: 0.0%–0.4%), which revealed great variability in the prevalence of comorbid tuberculosis amongst COVID-19 patients in different regions. Begg's test revealed that there was potential publication bias (P = .0017). In conclusion, our findings demonstrated that the prevalence of comorbid tuberculosis amongst COVID-19 patients was 1.6%, which varied greatly in different regions. We would like to thank Wenwei Xiao, Xuan Liang, Peihua Zhang, Yang Li and Jian Wu (All are from Department of Epidemiology, School of Public Health, Zhengzhou University) for their kind help in searching articles and collecting data. The authors declare that they have no any potential conflict of interest regarding this submitted manuscript. Yadong Wang and Haiyan Yang designed the study. Jie Xu, Ying Wang, Hongjie Hou and Li Shi performed literature search and data extraction. Jie Xu and Yadong Wang performed data analysis. Yadong Wang and Haiyan Yang wrote and reviewed the manuscript. All the authors approved the final manuscript. The data that support the findings of this study are included in this article and available from the corresponding author upon reasonable request.

Association between COVID-19 morbidity and mortality rates and BCG vaccination policies in OECD countries

On the relationship between BCG coverage and national COVID‐19 outcome: could ‘heterologous’ herd immunity explain why some countries are better off?

Association between live childhood vaccines and COVID-19 outcomes: a national-level analysis

BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden

The BCG Vaccine for COVID-19: First Verdict and Future Directions

[Progress in Possible Effects of BCG Vaccine on the Prevention of SARS-CoV-2 Infection: an Update]

Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: A randomised clinical trial

BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial

COVID-19 Severity and Neonatal BCG Vaccination among Young Population in Taiwan

Efficacy of Bacillus Calmette–Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial

Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland

BCG immunomodulation: From the ‘hygiene hypothesis’ to COVID-19

Safety profile of BCG revaccination for COVID prevention among elderly individuals in India

Prevalence of Comorbid Tuberculosis Amongst COVID‐19 Patients: A Rapid Review and Meta‐analysis

Determinants of COVID-19 cases and deaths in OECD countries

Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis

BCG Vaccine-The Road Not Taken

A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19

Covid-19 mortality and local burden of infectious diseases: A worldwide country-by-country analysis

The retrospective study of the metabolic patterns of BCG-vaccination in type-2 diabetic individuals in COVID-19 infection

Association between the incidence of type 1 diabetes mellitus and tuberculosis or bacillus Calmette-Guérin immunization in children and adolescents